Teachers Retirement System of The State of Kentucky Acquires Shares of 52,392 ADMA Biologics, Inc. (NASDAQ:ADMA)

Teachers Retirement System of The State of Kentucky purchased a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 52,392 shares of the biotechnology company’s stock, valued at approximately $1,047,000.

A number of other large investors have also recently modified their holdings of the company. State Street Corp increased its holdings in ADMA Biologics by 61.4% during the 3rd quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock worth $259,970,000 after purchasing an additional 4,945,063 shares during the period. D. E. Shaw & Co. Inc. grew its position in shares of ADMA Biologics by 26.8% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock worth $76,298,000 after buying an additional 1,442,799 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of ADMA Biologics by 2.6% during the third quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company’s stock valued at $107,606,000 after buying an additional 137,989 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of ADMA Biologics by 2.7% during the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after buying an additional 92,281 shares during the period. Finally, Driehaus Capital Management LLC raised its holdings in shares of ADMA Biologics by 17.3% in the second quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company’s stock valued at $33,860,000 after acquiring an additional 447,743 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares in the company, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 3.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on ADMA shares. HC Wainwright increased their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th. Finally, Raymond James lifted their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th.

ADMA Biologics Price Performance

Shares of ADMA stock opened at $17.70 on Thursday. The stock’s 50-day moving average is $18.90 and its 200 day moving average is $16.24. ADMA Biologics, Inc. has a 1-year low of $4.06 and a 1-year high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The company has a market cap of $4.18 billion, a P/E ratio of 63.21 and a beta of 0.70.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The business had revenue of $119.84 million for the quarter, compared to analysts’ expectations of $107.25 million. During the same period last year, the business earned $0.01 EPS. Research analysts predict that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.